CEP 37250

Drug Profile

CEP 37250

Alternative Names: ART 104; CEP-37250; KHK 2804; SC 104

Latest Information Update: 15 Feb 2016

Price : $50

At a glance

  • Originator Scancell
  • Developer Kyowa Hakko Kirin; Teva Pharmaceutical Industries
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 27 Oct 2011 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) in USA (Parenteral)
  • 09 Mar 2011 Preclinical development is ongoing
  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top